Will Mounjaro Help PCOS? What We Know, and What to Discuss with Your Doctor

What the evidence actually shows about PCOS and tirzepatide

There is no large, dedicated clinical trial of tirzepatide in women with PCOS specifically. That is worth saying plainly. What exists is a strong body of evidence for tirzepatide's effects on weight and insulin resistance, both of which sit at the heart of PCOS for many women.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, found average body-weight reductions of around 20–21% at the highest dose over 72 weeks. Participants did not have PCOS as a primary inclusion criterion, but the metabolic improvements (reduced fasting insulin, improved lipid profiles, lower inflammatory markers) are mechanisms that matter in PCOS. Insulin resistance drives many of the most difficult PCOS symptoms: irregular periods, raised androgens, skin changes, and difficulty losing weight. Reducing it tends to reduce them.

Smaller studies and real-world reports suggest GLP-1 based medicines may improve menstrual regularity and androgen levels alongside weight loss in women with PCOS, but the evidence base is still building. What we currently know about Mounjaro and PCOS outcomes is promising rather than definitive. Prescribers weigh that distinction seriously.

The NHS notes that weight management is one of the most effective interventions for PCOS symptoms in women who are overweight. Mounjaro's role, where it fits, is as part of that broader strategy.

The decision your prescriber actually needs to make

Even if you qualify on BMI, suitability for Mounjaro involves more than a number on a scale. A prescriber will want to understand your PCOS history: how it was diagnosed, whether you have insulin resistance confirmed, what medications you are already taking (metformin is common in PCOS management, and the combination with tirzepatide warrants clinical discussion), your contraceptive situation, and whether you are trying to conceive.

That last point matters more for women with PCOS than for many other patients. One of the effects of losing weight with PCOS is that ovulation can resume, sometimes faster than expected. Mounjaro is not recommended during pregnancy, and the MHRA advises using contraception throughout treatment. Women on the oral contraceptive pill should use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying may reduce pill absorption. Guidance on Mounjaro and pregnancy planning covers the wash-out period and what to discuss with your doctor before trying to conceive.

Mounjaro is also not recommended while breastfeeding. Under-18s are outside the licensed indication entirely.

If you keep your weekly pen in the fridge door alongside your morning medication, it is easy to build into a routine, but none of that routine should start without clinical sign-off, and in PCOS particularly, the prescriber's initial assessment is where individual risk factors come to light. You can explore whether tirzepatide is appropriate alongside other PCOS treatments for more on co-medication considerations.

What remains uncertain, and who should make this call

The honest answer is that PCOS is not uniform. Some women have it primarily as an insulin-resistance condition with significant weight involvement; others have a lean phenotype where the weight-loss angle is less relevant. For the former group, the case for exploring tirzepatide is stronger. For the latter, the evidence is thinner and the risk-benefit balance needs careful thought.

There is also ongoing research into tirzepatide's direct hormonal effects (separate from weight loss) on androgen levels and ovarian function. The emerging evidence on tirzepatide and PCOS specifically is worth reading alongside any conversation with your doctor or gynaecologist, because the picture is still developing.

The right person to make this call is a prescriber who can see your full medical history. For women with PCOS already under the care of an endocrinologist or gynaecologist, looping them in is sensible. For women whose PCOS is managed by their GP, that conversation can happen at the same appointment where weight-management options are discussed.

At nume, a GPhC-registered Independent Prescriber reads your consultation personally, a real clinician, not software. If there are aspects of your PCOS history that affect suitability, they will tell you. You can read more about how tirzepatide and PCOS interact clinically, or look at our treatment options if you are ready to start that conversation. Our clinical team also publishes guidance on conditions like this for anyone who wants to read more before deciding.